Rakesh Kumar Nayak
Breast carcinoma is the most frequently diagnosed cancer and cause of cancer related deaths among women worldwide. Triple negative breast carcinoma (TNBC) is a subtype with poor outcomes. The current study aimed at evaluating the hormone receptor and HER2/neu status of the study population and to know the burden of triple negative breast carcinoma here. It also aimed at assessing TNBC’s response to various treatment modalities.
